Hone Health at $114M ARR growing 82% YoY
Jan-Erik Asplund
TL;DR: After launching a women's line in January 2025 and expanding into weight loss (GLP-1s) and longevity (metformin & glutathione), Sacra estimates Hone Health hit $113.5M in annual recurring revenue (ARR) in September 2025, up 82% YoY and up from $69.7M at the end of 2024, with monthly growth doubling from ~3% to ~6%. For more, check out our full report and dataset.
We first covered Hone Health as a testosterone replacement therapy (TRT) provider in February 2024 as they hit ~$55M in annual revenue in the early stages of their expansion into longevity & weight loss.
Key points from our 2025 update via Sacra AI:
- After launching their women’s line in January 2025 and expanding into weight loss (GLP1s) and longevity (metformin & glutathione), Sacra estimates Hone Health hit $113.5M in annual recurring revenue (ARR) in September 2025, up from $69.7M at the end of 2024, with growth doubling from ~3% compound monthly growth rate over the last 3 months (CMGR3) at the beginning of the year to ~6% as of September.
- Neither mass-market D2C telehealth giants Hims & Hers (NYSE: HIMS, $2B in TTM revenue, up 36% YoY) nor Ro ($1.03B raised, FirstMark) have competitive offerings today on TRT or menopause HRT (with Hims targeting 2026), as they operate as purely virtual, high-volume prescription businesses shipping products direct to consumers across ED/hair/skin/GLP-1s, without Hone’s ops infrastructure for blood draws, lab evaluations, and quarterly follow-up consultations.
- Longevity-centric diagnostics platforms like Function Health ($100M annualized revenue in February 2025) and Superpower ($30M Series A, Forerunner) sell testing & insights via biannual 100+ biomarker panels without prescribing medications, while Hone Health bundles its blood tests into a personalized subscription ($129-$149/month) that combines diagnostics with ongoing treatment, prescribing hormones, metabolics and injectables based on results and tracking progress over time via physician consults.
For more, check out this other research from our platform:
- Hone Health (dataset)
- Function Health (dataset)
- Maven Clinic at $268M ARR
- BillionToOne at $153M/yr
- Commure at $105M ARR
- Oura at $225M
- Virta Health at $175M revenue
- Noom at $1B ARR
- Hone Health: the $55M/year D2C testosterone startup
- Sweden’s $215M/year telehealth giant
- Johannes Schildt & Claes Ruth, CEO and CFO of Kry, on the AI future of telehealth
- Ro and the telehealth capital cycle
- Marc Atiyeh, CEO of Pawp, on building telehealth for pets
- Kathryn Cross, CEO of Anja Health, on the future of stem cell therapy
- Liana Guzmán, CEO of Folx, on the $400B market for LGBTQIA healthcare
- Brendan Keeler, Senior PM at Zus Health, on building infrastructure for digital health
Read more from
Read more from
Rula revenue, growth, and valuation
Unlocked Report
Continue Reading
